KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).

被引：2
|
作者：
Lee, Chung-Han
Li, Chenxiang
Perini, Rodolfo F.
Hoehn, Daniela
Albiges, Laurence
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4595
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime
    Goh, Jeffrey C.
    Lalani, Aly-Khan A.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Mendez-Vidal, Maria Jose
    Kopyltsov, Evgeny
    Tjulandin, Sergei
    Gordoa, Teresa Alonso
    Kozlov, Vadim
    Alyasova, Anna
    Winquist, Eric
    Maroto, Pablo
    Kim, Miso
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Rodriguez-Lopez, Karla
    Burgents, Joseph
    He, Cixin
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1222 - 1228
  • [32] A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC).
    Zhang, Xinyue
    Liu, Ruiqi
    Liu, Yang
    Wei, Wensu
    Zhang, Zhiling
    Gao, Jianming
    Guo, Shengjie
    Han, Hui
    Zhou, Fangjian
    Dong, Pei
    He, Liru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 557 - 557
  • [33] Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
    Choueiri, Toni K.
    Merchan, Jaime R.
    Figlin, Robert
    Mcdermott, David F.
    Arrowsmith, Edward
    Michaelson, M. Dror
    Tykodi, Scott S.
    Heath, Elisabeth, I
    Spigel, David R.
    D'Souza, Anishka
    Kassalow, Laurent
    Perini, Rodolfo F.
    Vickery, Donna
    Bauer, Todd M.
    LANCET ONCOLOGY, 2025, 26 (01): : 64 - 73
  • [34] First-line therapy in advanced Renal Cell Carcinoma A randomized, open-label Phase-III-Study Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib compared to Sunitinib Monotherapy as First-Line Treatment for locally advanced or metastatic Renal Cell Carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO
    Rexer, H.
    Bedke, J.
    UROLOGE, 2017, 56 (03): : 385 - 386
  • [35] A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
    Lara Jr, Primo N.
    Villanueva, Luis
    Ibanez, Carolina
    Erman, Mustafa
    Lee, Jae Lyun
    Heinrich, Daniel
    Lipatov, Oleg Nikolaevich
    Gedye, Craig
    Gokmen, Erhan
    Acevedo, Alejandro
    Semenov, Andrey
    Park, Se Hoon
    Gafanov, Rustem Airatovich
    Kose, Fatih
    Jones, Mark
    Du, Xiaoqi
    Munteanu, Mihaela
    Perini, Rodolfo
    Choueiri, Toni K.
    Motzer, Robert J.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [36] Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
    Mortier, Laurent
    Villabona, Lisa
    Lawrence, Ben
    Arance, Ana
    Butler, Marcus O.
    Beylot-Barry, Marie
    Saiag, Philippe
    Samimi, Mahtab
    Ascierto, Paolo A.
    Spada, Francesca
    De Pontville, Michel
    Maio, Michele
    Berrocal, Alfonso
    Espinosa, Enrique
    Capdevila, Jaume
    Levin, Max
    Das, Debasmita
    Krepler, Clemens
    Grebennik, Dmitri
    Chiarion-Sileni, Vanna
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (06) : 987 - 996
  • [37] Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress
    Sun, J.
    Enzinger, P.
    Adenis, A.
    Shah, M.
    Kato, K.
    Bennouna, J.
    Doi, T.
    Hawk, N.
    Yu, L.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S352 - S352
  • [38] First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
    Buti, Sebastiano
    Bersanelli, Melissa
    Massari, Francesco
    De Giorgi, Ugo
    Caffo, Orazio
    Aurilio, Gaetano
    Basso, Umberto
    Carteni, Giacomo
    Caserta, Claudia
    Galli, Luca
    Boccardo, Francesco
    Procopio, Giuseppe
    Facchini, Gaetano
    Fornarini, Giuseppe
    Berruti, Alfredo
    Fea, Elena
    Naglieri, Emanuele
    Petrelli, Fausto
    Iacovelli, Roberto
    Porta, Camillo
    Mosca, Alessandra
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 1037 - 1046
  • [39] Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
    Motzer, Robert J.
    Hutson, Thomas E.
    Glen, Hilary
    Michaelson, M. Dror
    Molina, Ana
    Eisen, Timothy
    Jassem, Jacek
    Zolnierek, Jakub
    Pablo Maroto, Jose
    Mellado, Begona
    Melichar, Bohuslav
    Tomasek, Jiri
    Kremer, Alton
    Kim, Han-Joo
    Wood, Karen
    Dutcus, Corina
    Larkin, James
    LANCET ONCOLOGY, 2015, 16 (15): : 1473 - 1482
  • [40] Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
    Graham, Jeffrey
    Wells, Connor
    Dudani, Shaan
    Gan, Chun Loo
    Donskov, Frede
    Lee, Jae-Lyun
    Kollmannsberger, Christian K.
    Pal, Sumanta K.
    Beuselinck, Benoit
    Hansen, Aaron Richard
    North, Scott A.
    Bjarnason, Georg A.
    Agarwal, Neeraj
    Kanesvaran, Ravindran
    Wood, Lori
    Hotte, Sebastien J.
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345